Published Research

Vicus develops its breakthrough adjunct therapies based on the published research of leading physicians and scientists.

Cancer, Systemic Inflammation and Cachexia.

N. MacDonald, Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care, J Support Oncol. 2007;Apr. 5(4):157-62.

D.C. McMillan, Systemic inflammation, nutritional status and survival in patients with cancer.  Curr Opin Clin Nutr Metab Care 2009; May 12(3):223-6.

E. Van Custem et al, The causes and consequences of cancer-associated malnutrition, Eur J Oncol Nurs. 2005;9 Suppl 2:S51-63.

VT-122 Phase 2 clinical trial and animal study results.

G.S. Bhattacharyya et al.  Phase II study evaluating safety and efficacy of coadministering  propranolol and etodolac for treating cancer cachexia.  J Clin Oncol. 2010; 28(suppl; abstr e18059).

A. Glasner et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol. 2010; 184(5):2449-57.

Beta blocker for cancer, systemic inflammation and cachexia.

A. Gambardella et al., Intralipid infusion combined with propranolol administration has favorable metabolic effects in elderly malnourished cancer patients, Metabolism 1999; Mar. 48(3):291-7.

D.N. Herndon et al., Reversal of catabolism by beta-blockade after severe burns, N Engl J Med. 2001; Oct. 25,345(17):1223-9.

A. Hyltander et al., Beta-adrenoceptor activity and resting energy metabolism in wegiht losing cancer patients, Eur J Cancer. 2000,Feb;36(3):330-4.

C.Léauté-Labrèze et al., Propranolol for severe hemangiomas of infancy, N Engl J Med. 2008; June 12,358(24):2649-51.

D. Powe et al., Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival, Oncotarget; 2010 Nov 1,(7):628-38.

E.K. Sloan et al., The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer, Cancer Res. 2010; Sep 7.

NSAIDs for cancer, systemic inflammation and cachexia.

J. Behari et al., R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells, J Heptol,  2007 May;46(5):849-57.

A.T. Chan et al., Aspirin use and survival after diagnosis of colorectal cancer, JAMA. 2009; Aug. 12, 302(6):649-58.

D.C. McMillan et al., A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss, Br J Cancer 1999; 79(3-4):495-500.